Development and use of palivizumab (Synagis): a passive immunoprophylactic agent for RSV

P. Pollack,J. Groothuis,G. M. Barbarotto
DOI: https://doi.org/10.1007/S10156-002-0178-6
IF: 2.065
Journal of Infection and Chemotherapy
Abstract:
What problem does this paper attempt to address?